Intranasal Delivery of Nerve Growth Factor in Neurodegenerative Diseases and Neurotrauma
Since the 1980s, the development of a pharmacology based on nerve growth factor (NGF) has been postulated for the therapy of Alzheimer’s disease (AD). This hypothesis was based on the rescuing effect of the neurotrophin on the cholinergic phenotype of the basal forebrain neurons, primarily compromis...
Enregistré dans:
Auteurs principaux: | Luigi Manni, Giorgio Conti, Antonio Chiaretti, Marzia Soligo |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Frontiers Media S.A.
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/c61e5f160f2b4259aaf62ed2afadf5df |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
The Evolving Concept of Neuro-Thromboinflammation for Neurodegenerative Disorders and Neurotrauma: A Rationale for PAR1-Targeting Therapies
par: Barry W. Festoff, et autres
Publié: (2021) -
Encapsulated Escitalopram and Paroxetine Intranasal Co-Administration: In Vitro/In Vivo Evaluation
par: Soraia Silva, et autres
Publié: (2021) -
Immunomodulation induced by central nervous system‐related peptides as a therapeutic strategy for neurodegenerative disorders
par: María Laura Palumbo, et autres
Publié: (2021) -
Reversed phase HPLC determination of zidovudine in rat plasma and its pharmacokinetics after a single intranasal dose administration
par: MAINARDES,RUBIANA M, et autres
Publié: (2009) -
The Emerging Scenario of the Gut–Brain Axis: The Therapeutic Actions of the New Actor Kefir against Neurodegenerative Diseases
par: Thiago M. C. Pereira, et autres
Publié: (2021)